Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom improvement
RCT 4-armed trial	229 people with plaque psoriasis involving at least 10% of body surface	Proportion of people with at least a 75% decrease in baseline Psoriasis Area and Severity Index (PASI) score 12 weeks after the end of treatment 33% with alefacept 0.025 mg/kg 31% with alefacept 0.075 mg/kg 19% with alefacept 0.150 mg/kg 11% with placebo Absolute results reported graphically	P = 0.02 for any dose v placebo	Effect size not calculated	alefacept
RCT	553 people with plaque psoriasis involving at least 10% of body surface area	Proportion of people with at least a 75% decrease in baseline PASI score 2 weeks after treatment 53/367 (14%) with intravenous alefacept 7.5 mg once weekly for 12 weeks 7/186 (4%) with placebo for 12 weeks	P <0.001	Effect size not calculated	alefacept
RCT 3-armed trial	507 people with chronic plaque psoriasis involving a mean 21% of body surface area	Proportion of people with at least a 75% decrease in baseline PASI score 12 weeks after the end of treatment 28% with intramuscular alefacept 10 mg once weekly 33% with intramuscular alefacept 15 mg once weekly 13% with placebo once weekly Absolute numbers not reported	Reported as significant P <0.001 for alefacept at either dose v placebo	Effect size not calculated	alefacept